Bas D. Koster

High and Interrelated Rates of PD-L1+CD14+ Antigen-Presenting Cells and Regulatory T Cells Mark the Microenvironment of Metastatic Lymph Nodes from Patients with Cervical Cancer

A. Marijne Heeren, Bas D. Koster, Sanne Samuels et al. · Cancer Immunology Research · 2014 · 114 citations

Medicine, Immunology, Oncology +17

Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I–II Melanoma: Data from Two Randomized Phase II Trials

Bas D. Koster, Mari F.C.M. van den Hout, Berbel J.R. Sluijter et al. · Clinical Cancer Research · 2017 · 64 citations · Full text

Medicine, Immunology, Oncology +17

Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141+ Dendritic Cells and Enhanced Cross-Presentation

Berbel J.R. Sluijter, Mari F.C.M. van den Hout, Bas D. Koster et al. · Cancer Immunology Research · 2015 · 63 citations

Life Sciences, Immunology, Oncology +17

Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic T _reg reduction and effector T cell activation

Kim M. van Pul, Jessica C.L. Notohardjo, Marieke F. Fransen et al. · Science Immunology · 2022 · 56 citations

Medicine, Immunology, Oncology +17

Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence

Mari F.C.M. van den Hout, Bas D. Koster, Berbel J.R. Sluijter et al. · Cancer Immunology Research · 2017 · 53 citations

Life Sciences, Immunology, Oncology +17